Daldal Hatice, Turkyilmaz Mustafa, Balikoglu Yilmaz Melike, Berberoglu Ufuk
Faculty of Medicine, Usak University, 64000 Usak, Turkey.
Tarsus State Hospital, 33460 Mersin, Turkey.
Clin Pract. 2021 Sep 14;11(3):659-670. doi: 10.3390/clinpract11030081.
To investigate the changes in vision-related quality of life after a loading dose of three consecutive intravitreal ranibizumab (IVR) injections in patients with unilateral diabetic macular edema (DME).
Fifty-two eyes of 52 patients who received IVR injections in only one eye with DME were included in our study. The following characteristics of the patients were recorded: gender, education status, marital status, work status, presence of chronic disease. The changes in best-corrected visual acuity (BCVA) and central macular thickness (CMT) were evaluated at baseline (before treatment) and 1 month after the third intravitreal injection (after treatment). Patients were administered the Turkish form of the National Eye Institute 25-Item Visual Functions Questionnaire (NEI VFQ-25 TR). The quality of life scores assessed by the NEI VFQ-25 TR, the BCVA, intraocular pressure (IOP), and CMT measurements were compared at baseline (before treatment) and 1 month after the third intravitreal injection (after treatment).
We enrolled 52 patients (25 females, 27 males) in our study; mean age was 64.35 ± 9.26 years. After treatment, BCVA improved significantly ( = 0.001), and macular thickness decreased significantly ( < 0.001). All NEI VFQ-25 TR subscale scores were significantly higher after treatment ( < 0.05). However, no significant correlation was found between the change in BCVA and CMT and the change in NEI VFQ-25 TR subscale and composite scores. The increase in near activities scores was significantly higher in males ( = 0.020) and in the retired group ( = 0.022). There were no significant differences in the changes in NEI VFQ-25 TR subscale and composite scores in relation to educational status.
Significant improvements in BCVA, macular edema, and vision-related quality of life were found in DME patients who received IVR injections with a loading dose, as shown by the NEI VFQ-25 TR. Interestingly, a significant improvement in quality of life was observed even though the patients could see well with the fellow eye. In conclusion, the NEI VFQ-25 TR is a useful scale to evaluate the changes in visual function and psychosocial characteristics of DME patients after treatment.
研究单侧糖尿病性黄斑水肿（DME）患者连续3次玻璃体内注射雷珠单抗（IVR）负荷剂量后视力相关生活质量的变化。
本研究纳入52例仅一只眼患有DME并接受IVR注射的患者的52只眼。记录患者的以下特征：性别、教育程度、婚姻状况、工作状况、慢性病情况。在基线期（治疗前）和第三次玻璃体内注射后1个月（治疗后）评估最佳矫正视力（BCVA）和中心黄斑厚度（CMT）的变化。患者接受了土耳其语版的美国国立眼科研究所25项视觉功能问卷（NEI VFQ - 25 TR）。比较基线期（治疗前）和第三次玻璃体内注射后1个月（治疗后）通过NEI VFQ - 25 TR评估的生活质量得分、BCVA、眼压（IOP）和CMT测量值。
本研究纳入52例患者（25例女性，27例男性）；平均年龄为64.35±9.26岁。治疗后，BCVA显著改善（P = 0.001），黄斑厚度显著降低（P < 0.001）。治疗后所有NEI VFQ - 25 TR子量表得分均显著升高（P < 0.05）。然而，BCVA和CMT的变化与NEI VFQ - 25 TR子量表及综合得分的变化之间未发现显著相关性。男性（P = 0.020）和退休组（P = 0.022）的近视力活动得分增加显著更高。NEI VFQ - 25 TR子量表及综合得分的变化在教育程度方面无显著差异。
如NEI VFQ - 25 TR所示，接受IVR负荷剂量注射的DME患者的BCVA、黄斑水肿和视力相关生活质量有显著改善。有趣的是，即使患者另一只眼视力良好，生活质量仍有显著改善。总之，NEI VFQ - 25 TR是评估DME患者治疗后视觉功能和心理社会特征变化的有用量表。
